ArticleRenal failure2026
Epigallocatechin-3-gallate attenuates oxidative stress and apoptosis in podocytes of focal segmental glomerulosclerosis.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal segmental glomerulosclerosis (FSGS) is a major pathological feature of kidney injury, with limited therapeutic options currently available. This study aims to investigate the core mechanisms of podocyte injury in FSGS and the therapeutic potential of the natural extract epigallocatechin-3-gallate (EGCG). Through single-nucleus RNA sequencing of kidney tissues from patients with primary FSGS and an adriamycin (ADR)-induced nephropathy mouse model, we identified a subpopulation of injured podocytes. We found that damaged podocytes exhibited significantly elevated reactive oxygen species (ROS) levels and increased apoptotic activity compared to healthy podocytes. In animal experiments, EGCG treatment effectively reduced the elevation of the urine albumin-to-creatinine ratio, significantly alleviated glomerulosclerosis, and attenuated the ADR-induced decrease in the reduced glutathione/oxidized glutathione ratio in both serum and renal tissues of ADR-treated mice. Furthermore,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.